MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
28.55
-0.20
-0.70%
Pre Market: 31.74 +3.19 +11.17% 06:08 02/12 EST
OPEN
28.52
PREV CLOSE
28.75
HIGH
28.98
LOW
27.17
VOLUME
4.10K
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
18.92
MARKET CAP
3.23B
P/E (TTM)
-13.4784
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-Viking jumps on plans to advance oral obesity drug to late-stage testing
Reuters · 2h ago
Viking To Advance Oral VK2735 Into Phase 3 Trial For Obesity In 3Q26; Stock Up Over 10%
NASDAQ · 2h ago
VIKING THERAPEUTICS SHARES UP 11.7% PREMARKET AS CO PLANS TO ADVANCE ORAL OBESITY DRUG TO LATE-STAGE TESTING
Reuters · 2h ago
Why Fastly Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Benzinga · 3h ago
These Are the Stocks Reporting Earnings Today – February 12, 2026
TipRanks · 3h ago
Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
Seeking Alpha · 7h ago
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), CSL (CMXHF)
TipRanks · 12h ago
BUZZ-Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies
Reuters · 14h ago
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.